|
OMB APPROVAL
|
|
OMB
Number:
|
3235-0058
|
|
Expires:
|
28-Feb-22
|
|
Estimated average
burden
hours per
response
|
2.50
|
|
SEC FILE
NUMBER
|
|
|
|
CUSIP NUMBER
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check one):
[ ] Form 10-K [ ] Form 20-F [
] Form 11-K [X] Form 10-Q [ ]
Form 10-D [ ] Form N-CE [ ]
Form N-CSR
For Period
Ended: September 30,
2020
|
[
]
|
Transition Report on
Form 10-K
|
|
[
]
|
Transition Report on
Form 20-F
|
|
[
]
|
Transition Report on
Form 11-K
|
|
[
]
|
Transition Report on
Form 10-Q
|
For the
Transition Period Ended: __________
|
Read Instruction (on back page) Before Preparing Form. Please
Print or Type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
|
|
|
|
If the notification
relates to a portion of the filing checked above, identify the
item(s) to which the notification relates:
|
|
|
PART I -
REGISTRANT INFORMATION
|
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
|
|
Full Name of Registrant
|
|
|
|
|
|
Former Name if Applicable
|
|
|
|
4093 Oceanside Boulevard, Suite B
|
|
Address of Principal Executive Office (Street and Number)
|
|
|
|
Oceanside, California 92056
|
|
City, State and Zip Code
|
SEC 1344 (06-19)
PART II - RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
(a)The
reason described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or
expense;
[X](b)The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or
portion thereof, will be filed on or
before the fifteenth calendar day following the prescribed due date;
or the subject quarterly report or transition report on Form 10-Q
or subject distribution report on Form 10-D, or portion thereof,
will be filed on or before the fifth calendar day following the
prescribed due date; and
(c)The
accountant’s statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
Persons who are to respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number.
PART III – NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D,
N-CEN, N-CSR, or the transition report or portion thereof, could
not be filed within the prescribed time period.
Due
to continued delays caused by COVID-19 that continue to cause
severe disruptions in transportation and limited access to the
Company’s facilities resulting in limited support from its staff
and professional advisors, the Company is unable to file its
quarterly report on Form 10-Q for the period ended September 30,
2020 within the prescribed time period due to its difficulty in
completing and obtaining required financial and other information
without unreasonable effort and expense. The 10-Q will be filed on
or before the fifth calendar day following the extended due date not
falling on a holiday or weekend, which would be November 23,
2020.
(Attach extra Sheets if Needed)
PART IV - OTHER INFORMATION
(1)Name
and telephone number of person to contact in regard to this
notification
|
Timothy G. Dixon, CEO
|
|
760
|
|
295-7208
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone Number)
|
(2)Have
all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If answer is no, identify report(s). Yes [X]
No [ ]
(3)Is
it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof? Yes [ ] No [X]
If
so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be
made.
|
THERAPEUTIC SOLUTIONS INTERNTATIONAL, INC.
|
|
(Name
of Registrant as Specified in Charter)
|
has caused this
notification to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Date:
|
November 16, 2020
|
|
By:
|
Timothy G. Dixion,
CEO
|
INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name
and title of the person signing the form shall be typed or printed
beneath the signature. If the statement is signed on behalf of the
registrant by an authorized representative (other than an executive
officer), evidence of the representative’s authority to sign on
behalf of the registrant shall be filed with the form.
|
ATTENTION
|
|
Intentional misstatements or omissions of fact constitute
Federal Criminal Violations (See 18 U.S.C. 1001).
|
